Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.

Liang Y, Doré V, Rowe CC, Krishnadas N

Journal of Alzheimer's disease reports7 May 2024Cited by 54 (Europe PMC)

PMID38746639PMCIDPMC11091751DOI10.3233/adr-230181PepBankPUB-38746639

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with Alzheimer's disease, pooled GLP-1 receptor agonists did not change amyloid-beta or tau biomarkers at end of treatment versus placebo in two RCTs.
In plain wordsIn people with Alzheimer's disease, GLP-1 drugs as a group did not change amyloid or tau markers compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeAmyloid-beta and tau biomarkers
Study
n: not reported in source
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Two RCTs with amyloid-β and tau biomarker endpoints did not observe an end of treatment difference between the placebo and treated groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Six articles that met criteria were included (four randomized control trials [RCTs] and two protocol studies).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3874663901
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with Alzheimer's disease, pooled GLP-1 receptor agonists did not improve cognitive endpoints at end of treatment versus placebo in three RCTs.
In plain wordsIn people with Alzheimer's disease, GLP-1 drugs as a group did not improve thinking and memory scores compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeCognitive endpoints
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
In three RCTs with cognitive endpoints, there was no end of treatment difference between placebo and treated groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Six articles that met criteria were included (four randomized control trials [RCTs] and two protocol studies).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3874663902
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In the included Alzheimer's disease trials, pooled GLP-1 receptor agonists were associated with lower body mass index in treated groups.
In plain wordsIn Alzheimer's disease trials, groups given GLP-1 drugs as a class had lower body mass index.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RA showed metabolic benefits, such as lower body mass index and improved glucose levels on oral glucose tolerance tests in treated groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Six articles that met criteria were included (four randomized control trials [RCTs] and two protocol studies).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3874663903
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In the included Alzheimer's disease trials, pooled GLP-1 receptor agonists improved glucose levels on oral glucose tolerance tests in treated groups.
In plain wordsIn Alzheimer's disease trials, groups given GLP-1 drugs as a class had better glucose results on glucose tolerance tests.
Peptide
Liraglutide
Outcome
DecreaseGlucose on oral glucose tolerance test
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
GLP-1 RA showed metabolic benefits, such as lower body mass index and improved glucose levels on oral glucose tolerance tests in treated groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Six articles that met criteria were included (four randomized control trials [RCTs] and two protocol studies).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3874663904
05HumanNot a test of Liraglutide aloneSystematic reviewMechanism
Pooled GLP-1 receptor agonists may mitigate the decline in cerebral glucose metabolism and enhance blood-brain glucose transport on 18F-FDG PET; the review states more data are needed.
In plain wordsGLP-1 drugs as a class may slow the fall in brain glucose use in Alzheimer's disease, but the review says more data are needed.
Peptide
Liraglutide
Outcome
MixedCerebral glucose metabolism on 18F-FDG PET
Study
n: not reported in source
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
GLP-1 RA may mitigate the decline in cerebral glucose metabolism and show enhanced blood-brain glucose transport capacity using ¹⁸F-FDG PET, however, more data is needed.
1 context sentence(design, population, supporting numbers)
Summary · context
Six articles that met criteria were included (four randomized control trials [RCTs] and two protocol studies).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3874663905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.